A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular ...

In the trial SUSTAIN 6 (short for trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects ...

Baseline patient characteristics were well-balanced, including kidney function and albuminuria status. The primary endpoint ...

The remarkable secondary analysis from the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with ...

A 28-year-old woman in Oregon became paralyzed from the waist down after a grand piano fell on her and severed her spinal ...

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating ...

In this cohort study of living kidney donors and nondonors with the same follow-up schedule, the risks of hypertension and albuminuria were not significantly different. After the initial drop in ...

In addition to a 24% reduction in major kidney disease events, the semaglutide group had 18% less MACE at 3 years versus ...

The at-home test, known as a semi-quantitative test, uses a urine sample to measure the presence of albumin protein relative ...

(Journal of the American Heart Association) Living kidney donors did not have higher risks of hypertension and albuminuria in ...

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in ...

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction ...